A61K31/6615

COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS
20220233556 · 2022-07-28 ·

Methods and compositions that include the use NSAID derivatives for the treatment of dry eye disease, retinopathy, and related diseases are disclosed herein.

Composition and Concentrate for Use in Preparation of Dialysis Solution, Corresponding Dialysis Solution and Combinations Comprising Container
20220226356 · 2022-07-21 ·

Disclosed is a composition for use in preparation of a dialysis solution, at least comprising a first substance and a second substance, wherein the first substance comprises or can generate phosphate, and the second substance comprises or can generate a peptide based on glycine. Also disclosed are a corresponding dialysis solution, a corresponding concentrate, a combination of a container and the composition, a combination of a container and the dialysis solution and a combination of a container and the concentrate. According to the present disclosure, a more stable, more effective dialysis solution can be obtained.

Composition and Concentrate for Use in Preparation of Dialysis Solution, Corresponding Dialysis Solution and Combinations Comprising Container
20220226356 · 2022-07-21 ·

Disclosed is a composition for use in preparation of a dialysis solution, at least comprising a first substance and a second substance, wherein the first substance comprises or can generate phosphate, and the second substance comprises or can generate a peptide based on glycine. Also disclosed are a corresponding dialysis solution, a corresponding concentrate, a combination of a container and the composition, a combination of a container and the dialysis solution and a combination of a container and the concentrate. According to the present disclosure, a more stable, more effective dialysis solution can be obtained.

Combined preparations of urinary acidifiers and crystallization inhibitors and application thereof for the treatment or prevention of phosphatic or calcium phosphate-induced renal lithiasis

The present invention is related to the use of a separate, sequential or simultaneous combination of at least one urinary acidifier with at least one calcium phosphate crystallization inhibitor for urine acidification, and thus preventing the pH at which supersaturation of calcium phosphate is produced and consequently, renal lithiasis.

Combined preparations of urinary acidifiers and crystallization inhibitors and application thereof for the treatment or prevention of phosphatic or calcium phosphate-induced renal lithiasis

The present invention is related to the use of a separate, sequential or simultaneous combination of at least one urinary acidifier with at least one calcium phosphate crystallization inhibitor for urine acidification, and thus preventing the pH at which supersaturation of calcium phosphate is produced and consequently, renal lithiasis.

Combined preparations of urinary acidifiers and crystallization inhibitors and application thereof for the treatment or prevention of phosphatic or calcium phosphate-induced renal lithiasis

The present invention is related to the use of a separate, sequential or simultaneous combination of at least one urinary acidifier with at least one calcium phosphate crystallization inhibitor for urine acidification, and thus preventing the pH at which supersaturation of calcium phosphate is produced and consequently, renal lithiasis.

Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor
11202790 · 2021-12-21 · ·

The present invention provides a composition comprising a mixture of an exogenous ketone body, an exogenous NAD modulator and a methyl donor. Typically, exogenous NAD modulator is an exogenous nicotinamide adenine dinucleotide (NAD) precursor. The present invention also provides a method of using such a composition for treating various clinical conditions, including metabolic disorders and neurocognitive impairments. The compositions of the invention can also be used to improve human performance in various competitive or environmental conditions.

Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor
11202790 · 2021-12-21 · ·

The present invention provides a composition comprising a mixture of an exogenous ketone body, an exogenous NAD modulator and a methyl donor. Typically, exogenous NAD modulator is an exogenous nicotinamide adenine dinucleotide (NAD) precursor. The present invention also provides a method of using such a composition for treating various clinical conditions, including metabolic disorders and neurocognitive impairments. The compositions of the invention can also be used to improve human performance in various competitive or environmental conditions.

DRINK PRODUCT AND USE THEREOF
20210369745 · 2021-12-02 ·

A drink product having pharmaceutical compositions as an active ingredients of, at least one phosphorylated inositol, optionally Genistein, optionally Ubiquinol, and optionally additional unphosphorylated inositol. Uses for prevention, treatment, and reduction in risk of developing or progression of a number of conditions are disclosed.

DRINK PRODUCT AND USE THEREOF
20210369745 · 2021-12-02 ·

A drink product having pharmaceutical compositions as an active ingredients of, at least one phosphorylated inositol, optionally Genistein, optionally Ubiquinol, and optionally additional unphosphorylated inositol. Uses for prevention, treatment, and reduction in risk of developing or progression of a number of conditions are disclosed.